Related references
Note: Only part of the references are listed.Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Theresa Placke et al.
BLOOD (2014)
The Role of HTS in Drug Discovery at the University of Michigan
Martha J. Larsen et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2014)
Academic drug discovery centres: the economic and organisational sustainability of an emerging model
Henriette Schultz Kirkegaard et al.
DRUG DISCOVERY TODAY (2014)
Challenges and opportunities in targeting the menin- MLL interaction
Tomasz Cierpicki et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Structure- based design of small- molecule protein- protein interaction modulators: the story so far
Federico Falchi et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Affinity Map of Bromodomain Protein 4 ( BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
Marie Jung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development
Daqing Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein-Protein Interaction
Shihan He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies
Stephen M. Condon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia
Fang Cao et al.
MOLECULAR CELL (2014)
Drugging the p53 pathway: understanding the route to clinical efficacy (vol 13, pg 217, 2014)
Kian Hoe Khoo et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
K. Brinkmann et al.
CELL DEATH & DISEASE (2014)
Molecular therapeutic approches for pediatric acute myeloid leukemia
Sarah K. Tasian et al.
FRONTIERS IN ONCOLOGY (2014)
Oncogenic protein interfaces: small molecules, big challenges
Tracy L. Nero et al.
NATURE REVIEWS CANCER (2014)
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
Guillermo Senisterra et al.
BIOCHEMICAL JOURNAL (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Genetic profiling in acute myeloid leukaemia - where are we and what is its role in patient management
Yishai Ofran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Expanding the Number of 'Druggable' Targets: Non-Enzymes and Protein-Protein Interactions
Leah N. Makley et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Translational research: the changing landscape of drug discovery
C. Simone Fishburn
DRUG DISCOVERY TODAY (2013)
How to design a drug for the disordered proteins
Calvin Yu-Chian Chen et al.
DRUG DISCOVERY TODAY (2013)
Proteasome inhibitors in acute leukemia
Denise Niewerth et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
Anders Friberg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
Olivier Mirguet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of a Potent Inhibitor of Replication Protein A Protein- Protein Interactions Using a Fragment-Linking Approach
Andreas O. Frank et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Protein-Protein Interaction
Haibin Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein-Protein Interaction
Hacer Karatas et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Novel therapies for children with acute myeloid leukaemia
A. S. Moore et al.
LEUKEMIA (2013)
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer
Woojin Kim et al.
NATURE CHEMICAL BIOLOGY (2013)
2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions
Marie Jeanne Basse et al.
NUCLEIC ACIDS RESEARCH (2013)
Leukemia Fusion Target AF9 Is an Intrinsically Disordered Transcriptional Regulator that Recruits Multiple Partners via Coupled Folding and Binding
Benjamin I. Leach et al.
STRUCTURE (2013)
The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches
Orsola Vitagliano et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Binh Vu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction
Yuri Bolshan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
The evolving landscape in the therapy of acute myeloid leukemia
Grace L. Peloquin et al.
PROTEIN & CELL (2013)
Targeted drug discovery for pediatric leukemia
Andrew D. Napper et al.
FRONTIERS IN ONCOLOGY (2013)
Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
Sei-Hoon Yang
TUBERCULOSIS AND RESPIRATORY DISEASES (2013)
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
Qi Sun et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
The Pathogenesis of Mixed-Lineage Leukemia
Andrew G. Muntean et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 7 (2012)
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Duncan E. Scott et al.
BIOCHEMISTRY (2012)
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia
Aibin Shi et al.
BLOOD (2012)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases
L. D. Coles et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Fragment Based Drug Design: From Experimental to Computational Approaches
A. Kumar et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Julio Caballero et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
B. O. Villoutreix et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity
Matthew C. Smith et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2012)
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives
Giuseppe Giannini et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Relationship between Hot Spot Residues and Ligand Binding Hot Spots in Protein-Protein Interfaces
Brandon S. Zerbe et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
The same pocket in menin binds both MLL and JUND but has opposite effects on transcription
Jing Huang et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Jolanta Grembecka et al.
NATURE CHEMICAL BIOLOGY (2012)
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2012)
Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction
Lea Cunningham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mechanisms of leukemogenesis by MLL fusion proteins
Rolf Marschalek
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
Interactome Networks and Human Disease
Marc Vidal et al.
CELL (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX
Bonsu Ku et al.
CELL RESEARCH (2011)
Molecular complexity and fragment-based drug discovery: ten years on
Andrew R. Leach et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2011)
Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I)
Xavier Morelli et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2011)
Crystal Structure of Menin Reveals Binding Site for Mixed Lineage Leukemia (MLL) Protein
Marcelo J. Murai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Aromatic-Aromatic Interactions in Proteins: Beyond the Dimer
Esteban Lanzarotti et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Full Protein Flexibility Is Essential for Proper Hot-Spot Mapping
Katrina W. Lexa et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Cancer epigenetics reaches mainstream oncology
Manuel Rodriguez-Paredes et al.
NATURE MEDICINE (2011)
US academic drug discovery
Stephen Frye et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines.
Ashley J. Stevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Structural conservation of druggable hot spots in protein-protein interfaces
Dima Kozakov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKβ-NEMO interaction
Yusuke Gotoh et al.
ANALYTICAL BIOCHEMISTRY (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
MLL-AF9-Induced Leukemogenesis Requires Coexpression of the Wild-Type Mll Allele
Austin T. Thiel et al.
CANCER CELL (2010)
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Leandro C. Cerchietti et al.
CANCER CELL (2010)
Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective
Renato A. Bauer et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Molecular Basis of the Mixed Lineage Leukemia-Menin Interaction IMPLICATIONS FOR TARGETING MIXED LINEAGE LEUKEMIAS
Jolanta Grembecka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Analysis of the Binding of Mixed Lineage Leukemia 1 (MLL1) and Histone 3 Peptides to WD Repeat Domain 5 (WDR5) for the Design of Inhibitors of the MLL1-WDR5 Interaction
Hacer Karatas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Accessing new chemical space for 'undruggable' targets
Sivaraman Dandapani et al.
NATURE CHEMICAL BIOLOGY (2010)
The Structural Basis of Peptide-Protein Binding Strategies
Nir London et al.
STRUCTURE (2010)
Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules
Warren R. J. D. Galloway et al.
NATURE COMMUNICATIONS (2010)
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Leandro C. Cerchietti et al.
BLOOD (2009)
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Tamer E. Fandy
CURRENT MEDICINAL CHEMISTRY (2009)
The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions
Michelle R. Arkin et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Biophysical techniques for ligand screening and drug design
Jean-Paul Renaud et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Linking folding and binding
Peter E. Wright et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2009)
Targeting protein-protein interactions for therapeutic intervention: a challenge for the future
Giovanna Zinzalla et al.
FUTURE MEDICINAL CHEMISTRY (2009)
The molecular biology of mixed lineage leukemia
Robert K. Slany
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands
Erinna F. Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Cooperative binding of two acetylation marks on a histone tail by a single bromodomain
Jeanne Moriniere et al.
NATURE (2009)
The rise of fragment-based drug discovery
Christopher W. Murray et al.
NATURE CHEMISTRY (2009)
An empirical framework for binary interactome mapping
Kavitha Venkatesan et al.
NATURE METHODS (2009)
Novel targeted drug therapies I for the treatment of childhood acute leukemia
Patrick Brown et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Human Cancer Protein-Protein Interaction Network: A Structural Perspective
Gozde Kar et al.
PLOS COMPUTATIONAL BIOLOGY (2009)
Calorimetry and thermodynamics in drug design
Jonathan B. Chaires
ANNUAL REVIEW OF BIOPHYSICS (2008)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Sanjeev Shangary et al.
Annual Review of Pharmacology and Toxicology (2008)
Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails
Ying Liu et al.
BIOCHEMISTRY (2008)
Menin critically links MLL proteins with LEDGE on cancer-associated target genes
Akihiko Yokoyama et al.
CANCER CELL (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Aaron D. Schimmer et al.
CLINICAL CANCER RESEARCH (2008)
Peptide-mediated interactions in biological systems: new discoveries and applications
Evangelia Petsalaki et al.
CURRENT OPINION IN BIOTECHNOLOGY (2008)
Function and structure of inherently disordered proteins
A. Keith Dunker et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2008)
Protein–protein interactions as targets for small-molecule therapeutics in cancer
Alex W. White et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
Protein networks in disease
Trey Ideker et al.
GENOME RESEARCH (2008)
Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide
Anamika Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
WDR5 Interacts with Mixed Lineage Leukemia (MLL) Protein via the Histone H3-binding Pocket
Ji-Joon Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Fragment-Based Design of Small Molecule X-Linked Inhibitor of Apoptosis Protein Inhibitors
Jui-Wen Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
Cheol-Min Park et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Allostery: Absence of a change in shape does not imply that allostery is not at play
Chung-Jung Tsai et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer
Alexandru F. Ghetu et al.
MOLECULAR CELL (2008)
The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells
Christine M. Palermo et al.
LEUKEMIA RESEARCH (2008)
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Zhong Wang et al.
NATURE (2008)
Allosteric regulation and catalysis emerge via a common route
Nina M. Goodey et al.
NATURE CHEMICAL BIOLOGY (2008)
Perspectives on NMR in drug discovery: a technique comes of age
Maurizio Pellecchia et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Estimating the size of the human interactome
Michael P. H. Stumpf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces
James A. Wells et al.
NATURE (2007)
The design of drugs for HIV and HCV
Erik De Clercq
NATURE REVIEWS DRUG DISCOVERY (2007)
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group
D. Tomizawa et al.
LEUKEMIA (2007)
MLL translocations, histone modifications and leukaemia stem-cell development
Andrei V. Krivtsov et al.
NATURE REVIEWS CANCER (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFβ
Michael J. Gorczynski et al.
CHEMISTRY & BIOLOGY (2007)
High-throughput screening assays for the identification of chemical probes
James Inglese et al.
NATURE CHEMICAL BIOLOGY (2007)
Transient pockets on protein surfaces involved in protein-protein interaction
Susanne Eyrisch et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G
Nathan J. Moerke et al.
CELL (2007)
Hot spots-A review of the protein-protein interface determinant amino-acid residues
Irina S. Moreira et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
FLT3 inhibition in acute myeloid leukaemia
Steven Knapper
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Computational identification of inhibitors of protein-protein interactions
Shijun Zhong et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Trp/Met/Phe hot spots in protein-protein interactions: Potential targets in drug design
Buyong Ma et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Regulation of MLL1 H3K4 methyltransferase activity by its core components
Yali Dou et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Screening in a spirit haunted world
Brian K. Shoichet
DRUG DISCOVERY TODAY (2006)
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo
MD Wendt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology
Walter Huber et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Protein-protein interactions as targets for small molecule drug discovery
David C. Fry
BIOPOLYMERS (2006)
Targeting protein-protein interactions for cancer therapy
DC Fry et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
A Yokoyama et al.
CELL (2005)
Flexible nets - The roles of intrinsic disorder in protein interaction networks
AK Dunker et al.
FEBS JOURNAL (2005)
Protein-protein interactions in human disease
DP Ryan et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2005)
High-throughput assays for promiscuous inhibitors
BY Feng et al.
NATURE CHEMICAL BIOLOGY (2005)
Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF
YL Dou et al.
CELL (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Protein-protein interactions and cancer: small molecules going in for the kill
M Arkin
CURRENT OPINION IN CHEMICAL BIOLOGY (2005)
MLL: How complex does it get?
R Popovic et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
In-silico screening using flexible ligand binding pockets:: a molecular dynamics-based approach
D Sivanesan et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2005)
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
H Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
When epigenetics kills: MLL fusion proteins in leukemia
RK Slany
HEMATOLOGICAL ONCOLOGY (2005)
The evolving role of natural products in drug discovery
FE Koehn et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Hot regions in protein-protein interactions: The organization and contribution of structurally conserved hot spot residues
O Keskin et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
The modular architecture of protein-protein binding interfaces
D Reichmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Library design for fragment based screening
A Schuffenhauer et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Disruption of protein-protein interactions: Towards new targets for chemotherapy
A Loregian et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
MR Arkin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Conformational changes associated with protein-protein interactions
CS Goh et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2004)
MLL: a histone methyltransferase disrupted in leukemia
JL Hess
TRENDS IN MOLECULAR MEDICINE (2004)
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
KH Emami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Emerging classes of protein-protein interaction inhibitors and new tools for their development
L Pagliaro et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2004)
Use of a retroinverso p53 peptide as an inhibitor of MDM2
K Sakurai et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells
JM Polo et al.
NATURE MEDICINE (2004)
Protein-protein interactions: Hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: Implications for docking
X Li et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Libraries from natural product-like scaffolds
AM Boldi
CURRENT OPINION IN CHEMICAL BIOLOGY (2004)
A planning strategy for diversity-oriented synthesis
MD Burke et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain
KF Ahmad et al.
MOLECULAR CELL (2003)
Protein-protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces
BY Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Binding of small molecules to an adaptive protein-protein interface
MR Arkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini et al.
LANCET ONCOLOGY (2003)
MLL targets SET domain methyltransferase activity to Hox gene promoters
TA Milne et al.
MOLECULAR CELL (2002)
Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis
SM Lukasik et al.
NATURE STRUCTURAL BIOLOGY (2002)
Predicting changes in the stability of proteins and protein complexes: A study of more than 1000 mutations
R Guerois et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Optical biosensors in drug discovery
MA Cooper
NATURE REVIEWS DRUG DISCOVERY (2002)
Inhibition of protein-protein association by small molecules: Approaches and progress
PL Toogood
JOURNAL OF MEDICINAL CHEMISTRY (2002)
A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors
JF Glickman et al.
JOURNAL OF BIOMOLECULAR SCREENING (2002)
Unraveling hot spots in binding interfaces: progress and challenges
WL DeLano
CURRENT OPINION IN STRUCTURAL BIOLOGY (2002)
Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators
SJ Demarest et al.
NATURE (2002)
Functional organization of the yeast proteome by systematic analysis of protein complexes
AC Gavin et al.
NATURE (2002)
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins
PM Ayton et al.
ONCOGENE (2001)
Energetic and functional contribution of residues in the core binding factor β (CBFβ) subunit to heterodimerization with CBFα
YY Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFβ
AJ Warren et al.
EMBO JOURNAL (2000)
BCL-6 in the pathogenesis of non-Hodgkin's lymphoma
BH Ye
CANCER INVESTIGATION (2000)